References
- Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in translation: obstacles to translational medicine. J. Transl. Med.2(1), 14 (2004).
- Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J. Proteome Res.6(9), 3371–3376 (2007).
- Durán MC, Martín-Ventura JL, Mas S et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol. Biol.357, 141–150 (2007).
- Martin-Ventura JL, Duran MC, Blanco-Colio LM et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation110(15), 2216–2219 (2004).
- Kardys I, Rifai N, Meilhac O et al. Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. Clin. Chem.54(1), 139–146 (2008).
- Martín-Ventura JL, Nicolas V, Houard X et al. Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol.26(6), 1337–1343 (2006).
- Lepedda AJ, Cigliano A, Cherchi GM et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis203(1), 112–118 (2009).
- Rayner K, Chen YX, McNulty M et al. Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. Circ. Res.103(2), 133–141 (2008).
- Blanco-Colio LM, Martín-Ventura JL, Muñoz-García B et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(4), 916–922 (2007).
- Kralisch S, Ziegelmeier M, Bachmann A et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in Type 2 diabetes and end-stage renal disease. Atherosclerosis199(2), 440–444 (2008).
- Carrero JJ, Ortiz A, Qureshi AR et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol.4(1), 110–118 (2009).
- Moreno JA, Muñoz-García B, Martín-Ventura JL et al. The CD163-expressing macrophages recognize and internalize TWEAK potential consequences in atherosclerosis. Atherosclerosis (2009) (In Press).
- Muñoz-García B, Martín-Ventura JL, Martínez E et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke37(8), 2044–2053 (2006).
- Vega de Ceniga M, Esteban M, Quintana JM et al. Search for serum biomarkers associated with abdominal aortic aneurysm growth--a pilot study. Eur. J. Vasc. Endovasc. Surg.37(3), 297–299 (2009).
- Engström G, Börner G, Lindblad B, Janzon L, Lindgärde F. Incidence of fatal or repaired abdominal aortic aneurysm in relation to inflammation-sensitive plasma proteins. Arterioscler. Thromb. Vasc. Biol.24(2), 337–341 (2004).
- Fontaine V, Touat Z, Mtairag el M et al. Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am. J. Pathol.164(6), 2077–2087 (2004).
- Ortiz-Muñoz G, Houard X, Martín-Ventura JL et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J. (2009) (In Press).
- Calvo E, Camafeita E, Diaz JF, Lopez JA. Mass spectrometry for studying the interaction between small molecules and proteins. Curr. Proteomics5(1), 20–34 (2008).
- Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem.77, 383–414 (2008).
- Köster H, Little DP, Luan P et al. Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions. Assay Drug Develop. Technol.5, 381–390 (2007).
- Kim K, Kim Y. Preparing multiple-reaction monitoring for quantitative clinical proteomics. Expert Rev. Proteomics6(3), 225–229 (2009).
- Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8), 971–983 (2006).
Website
- Fighting Aneurysmal Disease Project. www.fighting-aneurysm.org